Introduction
GLP-1 weight-loss injections are one of the most effective medical treatments for people who struggle to lose weight through lifestyle changes alone. These medications, including Mounjaro and Wegovy, help regulate appetite, stabilise blood sugar and support steady long-term weight reduction when used alongside healthy diet and exercise.Many of the benefits of these treatments have been demonstrated in large clinical studies [1][2].
This guide explains how GLP-1 weight-loss treatments work, who they are suitable for, expected results, possible side effects and how to use them safely.
What Are GLP-1 Weight-Loss Medications?
GLP-1 medications belong to a group of treatments known as GLP-1 receptor agonists, which copy the action of a natural hormone that helps control appetite, digestion and blood sugar levels [5].
GLP-1 treatments were originally created for type 2 diabetes and were later found to have significant weight-loss benefits in people without diabetes as well [4].
Examples of GLP-1 weight-loss injections include:
-
Mounjaro (tirzepatide). This works on GLP-1 and GIP receptors.
-
Wegovy (semaglutide). A weekly GLP-1 injection for weight loss.
-
Ozempic (semaglutide). Licensed for diabetes but sometimes used off-label for weight management.
How GLP-1 Weight-Loss Injections Work
GLP-1 medications support weight loss in several clinically proven ways.
1. Reduced appetite
They slow the rate the stomach empties, which helps you feel fuller for longer and reduces snacking [5].
2. Fewer cravings
These medicines act on areas of the brain that regulate hunger and reward, which can reduce cravings and help control portion sizes [6].
3. Better blood sugar control
GLP-1 treatments stabilise blood sugar levels, helping prevent energy dips and reducing cravings for high-sugar foods [4].
4. Balanced hormonal response
They support a healthier insulin response, which can be helpful for people with insulin resistance [4].
5. Steady and sustainable weight loss
Weight typically decreases gradually. Most people notice the biggest changes once they reach a maintenance dose.
Expected Weight-Loss Results
Weight loss varies depending on the medication, the starting dose, adherence and lifestyle changes.
Clinical studies show:
-
Wegovy can lead to an average reduction of about 15% of body weight over 68 weeks [1].
-
Mounjaro can lead to an average reduction of around 20 to 22.5% at higher doses[2].
These results are higher than those seen with most traditional weight-loss medicines.
Weight tends to reduce slowly and steadily. Most progress happens once the correct maintenance dose has been reached.
Who Is Suitable for GLP-1 Weight-Loss Treatment?
GLP-1 injections may be suitable for people who:
-
Have a BMI of 30 or above.
-
Have a BMI of 27 or above together with a weight-related condition such as high blood pressure, high cholesterol or pre-diabetes.
-
Have struggled to lose weight through lifestyle changes alone.
-
Are not pregnant or breastfeeding.
-
Are not taking medicines that could interact with GLP-1 treatments.
-
Have no medical conditions that make these medicines unsuitable.
These criteria are based on recognised weight management guidance, including NICE recommendations for obesity management [3]
Suitability is carefully checked during the online consultation.
How to Use GLP-1 Weight-Loss Injections
Most GLP-1 injections are taken once a week. Each pen comes with clear instructions for safe and effective use.
Key points to remember:
-
Inject into the stomach, thigh or upper arm.
-
Rotate injection sites each week.
-
Follow the recommended dose increase schedule.
-
Do not increase your dose earlier than advised.
-
Store the pens correctly. Most are refrigerated before first use.
If you miss a dose, follow the product guidance or contact the pharmacy team for advice.
Dosage and Titration Schedule
GLP-1 treatments start with a low dose so your body can adjust. The dose increases gradually over several weeks.
A typical titration might look like:
-
Weeks 1 to 4. Starting dose.
-
Weeks 5 to 8. Moderate dose.
-
Weeks 9 to 12. Higher dose.
-
Maintenance dose. The ongoing weekly dose that suits your response and tolerance.
Exact schedules vary between medications. Each product page will include full details.
Comparing GLP-1 Weight Loss Treatments
While all GLP-1 weight loss injections work by regulating appetite, individual treatments differ in how they act on metabolic pathways and how patients respond.
Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, which may lead to stronger appetite control and greater average weight loss for some patients. Wegovy (semaglutide) targets the GLP-1 receptor only and has a longer clinical track record with well-established dosing protocols.
To explore how these treatments compare in more detail, including effectiveness, suitability, and expected outcomes, see our dedicated Mounjaro weight-loss timeline & results guide, and our Wegovy weight-loss timeline and results guide.
How to Maximise Results with GLP-1 Weight Loss Injections
GLP-1 weight loss injections are highly effective at reducing appetite and supporting calorie control, but long-term results depend on how well treatment is supported by diet and lifestyle habits. Patients who combine medication with consistent behavioural changes tend to achieve more sustainable weight loss and better overall health outcomes.
To maximise results while using GLP-1 treatments such as Wegovy or Mounjaro, consider the following:
-
Follow a structured eating routine
Eating regular, balanced meals helps stabilise blood sugar levels and reduces the likelihood of overeating when appetite returns later in the day. -
Prioritise protein and nutrient-dense foods
Protein supports muscle mass during weight loss and helps maintain satiety, particularly as overall calorie intake decreases. -
Stay well hydrated
Dehydration can worsen common side effects such as nausea and fatigue. Drinking enough fluids throughout the day can improve tolerance and overall wellbeing. -
Eat slowly and listen to fullness cues
GLP-1 treatments increase feelings of fullness. Eating too quickly can lead to discomfort, nausea, or indigestion before your body has time to signal that you are full. -
Be consistent with lifestyle changes
Light to moderate physical activity, improved sleep, and routine habits all play an important role in maintaining steady weight loss alongside medication. -
Allow time for dose adjustments
Results often improve gradually as doses are increased under clinical supervision. Following your prescribed dosing schedule helps minimise side effects and optimise effectiveness.
Choosing the right foods can make a significant difference to both results and comfort during treatment. Our guide on what to eat while using weight loss injections
explains which food choices best support appetite control, reduce side effects, and help maintain long-term weight loss while using GLP-1 treatments.
Common Weight Loss Injection Side Effects
Most side effects are mild and improve as your body gets used to the medication.
Commonly reported effects include:
-
Nausea
-
Bloating
-
Indigestion
-
Diarrhoea or constipation
-
Tiredness
-
Reduced appetite
-
Mild discomfort at the injection site
If side effects persist, dose adjustments or practical steps at home can help. Read our guide to the most common side effects of weight loss medications and how to manage them for further information.
When GLP-1 Weight-Loss Injections Are Not Suitable
These treatments are not suitable for everyone.
They are usually avoided if you have:
-
A history of pancreatitis
-
Severe digestive conditions
-
Certain endocrine disorders
-
Pregnancy or breastfeeding
-
An allergy to any ingredient in the medication
Your online consultation will check all safety considerations before prescribing.
Start Your GLP-1 Treatment Safely
Complete our quick and secure online consultation. Our pharmacy team will review your answers and advise on the most suitable GLP-1 weight-loss treatment for you.
Start Your Weight Loss Consultation →FAQs
How long do GLP-1 weight-loss injections take to work?
Do GLP-1 injections work for everyone?
Can I switch from one GLP-1 medication to another?
Do I need to stay on GLP-1 injections long term?
Are GLP-1 injections safe if I have diabetes?
What should I do if I miss a dose?
What side effects can I expect?
Can I drink alcohol while using GLP-1 injections?
How do GLP-1 injections help with cravings?
Are GLP-1 injections suitable for people with stomach conditions?
References
1. Wegovy (Semaglutide) – Clinical Evidence
• STEP-1 Trial: Once-weekly semaglutide in adults with overweight or obesity – NEJM
• STEP-1 Clinical Trial Registration – ClinicalTrials.gov
• Semaglutide for weight management – PubMed
2. Mounjaro (Tirzepatide) – Clinical Evidence
• SURMOUNT-1 Trial: Tirzepatide for the treatment of obesity (20% weight-loss data) – NEJM
• SURMOUNT-1 Clinical Trial Registration – ClinicalTrials.gov
• Tirzepatide weight-loss outcomes – PubMed
• Tirzepatide dual GLP-1/GIP mechanism – PubMed
3. GLP-1 Receptor Agonist Mechanism
• How GLP-1 medications affect appetite, digestion, and blood sugar – NHS
• Overview of GLP-1 receptor agonists used for weight management – NICE
4. GLP-1 Effects on Blood Sugar & Insulin
• Overview of GLP-1 Agonist Mechanism (Insulin, Glucose & Digestion) – NHS
• Mechanism of Action: GLP-1 and Insulin Production– Diabetes UK
5. NICE Guidance
• NICE CG189 – Obesity: identification, assessment and management – NICE
Medically Reviewed by Our GPhC-Registered Pharmacists
Authored by:
Palvinder DeolSuperintendent Pharmacist
Over 25 years’ clinical experience.
GPhC: 2047066
This article was medically reviewed for accuracy, safety, and alignment with UK clinical standards. Learn about our medical review process →
Content last updated: 17th December 2025 · Next review: January 2026
GPhC Inspection Result
Inspection Outcome: All Standards Met ✅
Our digital-first pharmacy achieved rare “Good Practice” recognition during our GPhC inspection on 19 May 2025 — showcasing our commitment to safe, high-quality and innovative online healthcare.
View full inspection report →GPhC Registration No. 9012585 | Inspected 19 May 2025

